Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
108 studies found for:    Open Studies | "Hemophilia A"
Show Display Options
Rank Status Study
21 Recruiting To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
22 Recruiting Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment
Condition: Hemophilia A
Intervention: Drug: Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)
23 Recruiting Phase 3b Continuation Study of the Safety and Efficacy of Prophylactic BAX 855 in PTPs With Severe Hemophilia A
Condition: Hemophilia A
Intervention: Biological: PEGylated Recombinant Factor VIII
24 Recruiting An Open-label Extension Study of an Investigational Drug, ALN-AT3SC, in Patients With Moderate or Severe Hemophilia A or B
Conditions: Hemophilia A;   Hemophilia B
Intervention: Drug: ALN-AT3SC
25 Recruiting A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients
Conditions: Hemophilia A;   Hemophilia B
Interventions: Drug: ALN-AT3SC;   Drug: Sterile Normal Saline (0.9% NaCl)
26 Recruiting A Study of Once-Weekly Emicizumab in Children and Adolescents With Hemophilia A and Factor VIII (FVIII) Inhibitors
Condition: Hemophilia A
Intervention: Drug: Emicizumab
27 Recruiting Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Interventions: Drug: Concizumab;   Drug: placebo
28 Recruiting A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment
Condition: Hemophilia A
Interventions: Drug: Bypassing Agents;   Drug: FVIII Replacement
29 Not yet recruiting Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
Condition: Hemophilia A, Congenital
Intervention: Biological: Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973
30 Recruiting Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
Condition: Acquired Hemophilia A
Intervention: Biological: OBIZUR
31 Recruiting Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A
Condition: Severe Haemophilia A
Intervention: Biological: Human cl rhFVIII
32 Not yet recruiting A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa pegol
33 Unknown  Personalized Prediction of Tolerance and Immunogenicity in Hemophilia
Condition: Hemophilia A
Intervention:
34 Not yet recruiting Hemophilia Inhibitor Prevention (INHIBIT) Trial
Condition: Severe Hemophilia A
Intervention: Drug: Long-acting recombinant factor VIII Fc fusion protein
35 Not yet recruiting FEIBA Reconstitution Volume Reduction and Faster Infusion Study
Conditions: (High-titer) Factor IX Inhibitor;   Hemophilia A;   Hemophilia B;   (High-titer) Factor VIII Inhibitor
Intervention: Biological: Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)
36 Recruiting Factor Product Utilization and Health Outcomes in Patients With Hemophilia
Conditions: Hemophilia A, Congenital;   Hemophilia B, Congenital
Intervention:
37 Recruiting BAY81-8973 Pediatric Safety and Efficacy Trial
Condition: Haemophilia A
Intervention: Biological: Recombinant Factor VIII (BAY81-8973)
38 Unknown  Thrombin Generation Assay (TGA) as Predictive Test for Haemostatic. Effectiveness of FVIII Concentrates in Haemophiliac A With Inhibitors
Condition: Severe Hemophilia A With Inhibitor
Intervention: Other: TGA (Thrombin generation Assay)
39 Recruiting A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Patients With Inhibitors
Condition: Hemophilia A
Intervention: Drug: Emicizumab
40 Recruiting Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors
Conditions: Hemophilia A With Inhibitors;   Hemophilia B With Inhibitors
Interventions: Drug: CSL689;   Drug: Eptacog alfa (activated)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years